<!-- SOURCE TRACE
Template section: 2.1.3 - Patient exposure
Required sources: PBRER Section 5
Verification status: NOT VERIFIED
Missing inputs: Source verification
-->

# 1.2.1.3 Patient Exposure

**Page range:** 13â€“13

```text
1.2.1.3
Patient Exposure
Since the Developmental International Birth Date (DIBD) (20 December 2016), an
estimated total of 1034 patients have received pralsetinib in clinical trial participation.
Since the IBD (i.e, 04 September 2020) until DLP of the latest PBRER (3 March 2024),
an estimated cumulative total of 2,694 patients have received pralsetinib from marketing
experience. Additionally, a total of 502 patients enrolled and 449 received pralsetinib
through other therapeutic use like pre-approval access, compassionate use programs
and expanded access programs (Gavreto PBRER).
```